Dose and Fractionation in Radiation Therapy of Curative Intent for Non-Small Cell Lung Cancer: Meta-Analysis of Randomized Trials

International Journal of Radiation Oncology Biology Physics

Volumn 96, Issue 4, 2016, Pages 736-747

  Ramroth, Johanna ^a   Cutter, David J ^a   Darby, Sarah C ^a   Higgins, Geoff S ^a   McGale, Paul ^a   Partridge, Mike ^a   Taylor, Carolyn W ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL ORGANS; CHEMOTHERAPY; DISEASES; RADIATION; TOXICITY;

CONCURRENT CHEMOTHERAPY; CONFIDENCE INTERVAL; EQUIVALENT DOSE; METHODS AND MATERIALS; NON SMALL CELL LUNG CANCER; RANDOMIZED TRIAL; SQUAMOUS CELL CARCINOMA; TREATMENT METHODS;

RADIOTHERAPY;

ANTINEOPLASTIC AGENT;

AGE; ARTICLE; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER SURVIVAL; DOSIMETRY; EMBASE; ESOPHAGITIS; EXPLORATORY RESEARCH; EXTERNAL BEAM RADIOTHERAPY; HEART DISEASE; HUMAN; LUNG FIBROSIS; MEDIAN SURVIVAL TIME; MEDICAL GEOGRAPHY; META ANALYSIS; NON SMALL CELL LUNG CANCER; OVERALL SURVIVAL; PNEUMONIA; PRIORITY JOURNAL; RADIATION DOSE ESCALATION; RADIATION DOSE FRACTIONATION; RADIATION DOSE REDUCTION; RADIATION INJURY; RADIOTHERAPY DOSAGE; RANDOMIZED CONTROLLED TRIAL (TOPIC); SQUAMOUS CELL LUNG CARCINOMA; SURVIVAL ANALYSIS; AGED; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; LUNG NEOPLASMS; MIDDLE AGED; MORTALITY; MULTIMODALITY CANCER THERAPY;

AGED; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; COMBINED MODALITY THERAPY; DOSE FRACTIONATION; HUMANS; LUNG NEOPLASMS; MIDDLE AGED; RADIOTHERAPY DOSAGE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SURVIVAL ANALYSIS;

EID: 84992522131     PISSN: 03603016     EISSN: 1879355X     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2016.07.022     Document Type: Article

References (49)

1. 1 Ferlay, J., Soerjomataram, I., Dikshit, R., et al. Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 136 (2015), E359–E386.
2. 2 Quaresma, M., Coleman, M.P., Rachet, B., 40-year trends in an index of survival for all cancers combined and survival adjusted for age and sex for each cancer in England and Wales, 1971-2011: A population-based study. Lancet 385 (2015), 1206–1218.
3. 3 Govindan, R., Page, N., Morgensztern, D., et al. Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: Analysis of the Surveillance, Epidemiologic, and End Results database. J Clin Oncol 24 (2006), 4539–4544.
4. 4 Molina, J.R., Yang, P., Cassivi, S.D., et al. Non-small cell lung cancer: Epidemiology, risk factors, treatment, and survivorship. Mayo Clin Proc 83 (2008), 584–594.
5. 5 Perez, C.A., Stanley, K., Rubin, P., A prospective randomized study of various irradiation doses and fractionation schedules in the treatment of inoperable non-oat-cell carcinoma of the lungs. Preliminary report by the Radiation Therapy Oncology Group. Cancer 45 (1980), 2744–2753.
6. 6 Bradley, J.D., Paulus, R., Komaki, R., et al. Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): A randomised, two-by-two factorial phase 3 study. Lancet Oncol 16 (2015), 187–199.
7. 7 Rodrigues, G., Choy, H., Bradley, J., et al. Definitive radiotherapy in locally advanced non-small cell lung cancer: Executive summary of an American Society for Radiation Oncology (ASTRO) evidence-based clinical practice guideline. Pract Radiat Oncol 5 (2015), 141–148.
8. 8 Mauguen, A., Le Pechoux, C., Saunders, M.I., et al. Hyperfractionated or accelerated radiotherapy in lung cancer: An individual patient data meta-analysis. J Clin Oncol 30 (2012), 2788–2797.
9. 9 Yamoah, K., Showalter, T.N., Ohri, N., Radiation therapy intensification for solid tumors: A systematic review of randomized trials. Int J Radiat Oncol Biol Phys 93 (2015), 737–745.
10. 10 Zhang, Q.N., Wang, D.Y., Wang, X.H., et al. Non-conventional radiotherapy versus conventional radiotherapy for inoperable non-small-cell lung cancer: A meta-analysis of randomized clinical trials. Thorac Cancer 3 (2012), 269–279.
11. 11 Schild, S.E., Vokes, E.E., Pathways to improving combined modality therapy for stage III non-small cell lung cancer. Ann Oncol 27 (2016), 590–599.
12. 12 Komaki, R., Khalid, N., Langer, C.J., et al. Penetration of recommended procedures for lung cancer staging and management in the United States over 10 years: A Quality Research in Radiation Oncology survey. Int J Radiat Oncol Biol Phys 85 (2013), 1082–1089.
13. 13 O'Rourke, N., Roque, I.F.M., Farre Bernado, N., et al. Concurrent chemoradiotherapy in non-small cell lung cancer. Cochrane Database Syst Rev, 2010, CD002140.
14. 14 McAleese, J., Baluch, S., Drinkwater, K., The quality of curative-intent radiotherapy for non-small cell lung cancer in the UK. Clin Oncol (R Coll Radiol) 27 (2015), 498–504.
15. 15 Tai, P., Yu, E., Battista, J., et al. Radiation treatment of lung cancer: Patterns of practice in Canada. Radiother Oncol 71 (2004), 167–174.
16. 16 Routh, A., Hickman, B.T., Khansur, T., Report of a prospective trial: Split course versus conventional radiotherapy in the treatment of non small cell lung cancer. Radiat Med 13 (1995), 115–119.
17. 17 Partridge, M., Ramos, M., Sardaro, A., et al. Dose escalation for non-small cell lung cancer: Analysis and modelling of published literature. Radiother Oncol 99 (2011), 6–11.
18. 18 Siannis, F., Barrett, J.K., Farewell, V.T., et al. One-stage parametric meta-analysis of time-to-event outcomes. Stat Med 29 (2010), 3030–3045.
19. 19 Brookmeyer, R., Crowley, J., A confidence interval for the median survival time. Biometrics 38 (1982), 29–41.
20. 20 StataCorp. Stata Statistical Software: Release 13. 2013, StataCorp LP, College Station, TX.
21. 21 Baumann, M., Herrmann, T., Koch, R., et al. Final results of the randomized phase III CHARTWEL-trial (ARO 97-1) comparing hyperfractionated-accelerated versus conventionally fractionated radiotherapy in non-small cell lung cancer (NSCLC). Radiother Oncol 100 (2011), 76–85.
22. 22 Ball, D., Bishop, J., Smith, J., et al. A randomised phase III study of accelerated or standard fraction radiotherapy with or without concurrent carboplatin in inoperable non-small cell lung cancer: Final report of an Australian multi-centre trial. Radiother Oncol 52 (1999), 129–136.
23. 23 Saunders, M., Dische, S., Barrett, A., et al. Continuous, hyperfractionated, accelerated radiotherapy (CHART) versus conventional radiotherapy in non-small cell lung cancer: Mature data from the randomised multicentre trial. Radiother Oncol 52 (1999), 137–148.
24. 24 Schild, S.E., Stella, P.J., Geyer, S.M., et al. Phase III trial comparing chemotherapy plus once-daily or twice-daily radiotherapy in stage III non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 54 (2002), 370–378.
25. 25 Bonner, J.A., McGinnis, W.L., Stella, P.J., et al. The possible advantage of hyperfractionated thoracic radiotherapy in the treatment of locally advanced nonsmall cell lung carcinoma. Cancer 82 (1998), 1037–1048.
26. 26 Cox, J.D., Azarnia, N., Byhardt, R.W., et al. A randomized phase I/II trial of hyperfractionated radiation therapy with total doses of 60.0 Gy to 79.2 Gy: Possible survival benefit with greater than or equal to 69.6 Gy in favorable patients with Radiation Therapy Oncology Group stage III non-small-cell lung carcinoma: Report of Radiation Therapy Oncology Group 83-11. J Clin Oncol 8 (1990), 1543–1555.
27. 27 Slawson, R.G., Salazar, O.M., Poussin-Rosillo, H., et al. Once-a-week vs conventional daily radiation treatment for lung cancer: Final report. Int J Radiat Oncol Biol Phys 15 (1988), 61–68.
28. 28 Fu, S., Jiang, G., Wang, L., Hyperfractionated irradiation for non-small cell lung cancer (NSCLC): A phase II clinical trial. [Chinese] Chin J Oncol 16 (1994), 306–309.
29. 29 Belani, C.P., Wang, W., Johnson, D.H., et al. Phase III study of the Eastern Cooperative Oncology Group (ECOG 2597): Induction chemotherapy followed by either standard thoracic radiotherapy or hyperfractionated accelerated radiotherapy for patients with unresectable stage IIIA and B non-small-cell lung cancer. J Clin Oncol 23 (2005), 3760–3767.
30. 30 Sapkota, S., Kapoor, R., Aggrawal, A.N., A randomized trial comparing conventional fractionation versus accelerated hyperfractionation with three dimensional conformal radiotherapy (3D-CRT) and concurrent chemotherapy in unresectable non small cell lung cancer. Lung Cancer, 80, 2013, S27.
31. 31 Sause, W., Kolesar, P., Taylor, I.S., et al. Final results of phase III trial in regionally advanced unresectable non-small cell lung cancer: Radiation Therapy Oncology Group, Eastern Cooperative Oncology Group, and Southwest Oncology Group. Chest 117 (2000), 358–364.
32. 32 Reinfuss, M., Glinski, B., Kowalska, T., et al. Radiotherapy for stage III, inoperable, asymptomatic small cell lung cancer. Final results of a prospective randomized study (240 patients). [French] Cancer Radiother 3 (1999), 475–479.
33. 33 Wang, X.C., Wang, S.Y., Yang, S., et al. Late course three-dimensional conformal radiotherapy in patients with stage III non-small cell lung cancer. [Chinese] Di Yi Jun Yi Da Xue Xue Bao 25 (2005), 726–728.
34. 34 Wang, X.C., Huang, X.B., Ding, Y., et al. Three-dimensional conformal radiotherapy combined with stereotactic radiotherapy for locally advanced non-small cell lung cancer: Efficacy and complications. [Chinese] Nan Fang Yi Ke Da Xue Xue Bao 28 (2008), 1996–1998.
35. 35 Yu, X.J., Han, D.L., Liu, Z.J., et al. Accelerated hypofractionated 3-dimensional conformal radiotherapy vs conventional radiotherapy in locally advanced non-small cell lung cancer using PET/CT-derived plan: A prospectively randomized controlled trial. [Chinese] Tumor 34 (2014), 253–259.
36. 36 Zajusz, A., Behrendt, K., Nowicka, E., et al. Early results of continuous accelerated radiotherapy (CAIR) for LA-NSCLC patients. Radiother Oncol, 81, 2006, 951.
37. 37 Cheng, J., Wu, G., Li, Q., Clinical study of late-course hyperfractionated radiotherapy in the treatment of local advanced non-small cell lung cancer. China Oncol 14 (2004), 254–257.
38. 38 Cheng, W.F., Pan, J.J., Quian, F.Y., et al. The analyses of 81 patients with stage III non-small cell lung cancer treated by late course accelerated hyperfractionation radiotherapy. J Basic Clin Oncol 20 (2007), 54–56.
39. 39 Zhan, Y., Huang, C.J., Shi, G.Y., et al. Clinical trial of concomitant radiotherapy for stage III non-small cell lung cancer. China Oncol 17 (2007), 524–526.
40. 40 Zhu, X., Peng, B.Y., Zhang, Z.F., et al. The effects of hyperfractionated accelerated radiation therapy in the later stage after conventional radiation for non-small cell lung cancer. Chin Clin Oncol 5 (2000), 199–201.
41. 41 Belderbos, J., Walraven, I., van Diessen, J., et al. Radiotherapy dose and fractionation for stage III NSCLC. Lancet Oncol 16 (2015), e156–e157.
42. 42 Joiner, M., van der Kogel, A., (eds.) Basic Clinical Radiobiology, 4th ed., 2009, Hodder Arnold, London.
43. 43 Hardy, D., Liu, C.C., Cormier, J.N., et al. Cardiac toxicity in association with chemotherapy and radiation therapy in a large cohort of older patients with non-small-cell lung cancer. Ann Oncol 21 (2010), 1825–1833.
44. 44 Kong, F.M., Ten Haken, R., Eisbruch, A., et al. Non-small cell lung cancer therapy-related pulmonary toxicity: An update on radiation pneumonitis and fibrosis. Semin Oncol 32:2 Suppl 3 (2005), S42–S54.
45. 45 Bar-Ad, V., Ohri, N., Werner-Wasik, M., Esophagitis, treatment-related toxicity in non-small cell lung cancer. Rev Recent Clin Trials 7 (2012), 31–35.
46. 46 Price, K.A., Azzoli, C.G., Gaspar, L.E., Chemoradiation for unresectable stage III non-small cell lung cancer. Semin Thorac Cardiovasc Surg 20 (2008), 204–209.
47. 47 Yuan, S., Sun, X., Li, M., et al. A randomized study of involved-field irradiation versus elective nodal irradiation in combination with concurrent chemotherapy for inoperable stage III nonsmall cell lung cancer. Am J Clin Oncol 30 (2007), 239–244.
48. 48 Christodoulou, M., Bayman, N., McCloskey, P., et al. New radiotherapy approaches in locally advanced non-small cell lung cancer. Eur J Cancer 50 (2014), 525–534.
49. 49 Saunders, M., Dische, S., Barrett, A., et al. Continuous hyperfractionated accelerated radiotherapy (CHART) versus conventional radiotherapy in non-small-cell lung cancer: A randomised multicentre trial. Lancet 350 (1997), 161–165.